Howe Jill Ann — SEC insider filings
SEC reporting owner CIK 1892397. 13 insider filings on record with FilingPulse; latest filed 2026-11-16.
Transaction summary — filings shown
Covers all 13 filings on record, filed 2021-11-05 to 2026-11-16. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 3 legs across 3 filings — 45,500 shares, $35,295 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 14.
- Largest priced transaction: purchase of 20,000 shares @ $0.85 ($17,100) in Lineage Cell Therapeutics, Inc., filed 2026-11-16.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Lineage Cell Therapeutics, Inc. (LCTX) | Chief Financial Officer | 8 | 3 legs · 45,500 sh · $35,295 | — | 5 |
| BIORA THERAPEUTICS, INC. (BIOR) | Director | 5 | — | — | 9 |
Insider filings — Howe Jill Ann
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-16 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Purchase (P): 20,000 @ $0.85 | EDGAR |
| 2026-03-06 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Grant/award (A): 1,050,000 (derivative) @ $0 | EDGAR |
| 2025-03-12 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Grant/award (A): 750,000 (derivative) @ $0 | EDGAR |
| 2024-11-26 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Purchase (P): 15,000 @ $0.59 | EDGAR |
| 2024-08-19 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Purchase (P): 10,500 @ $0.89 | EDGAR |
| 2024-06-06 | 4 | BIORA THERAPEUTICS, INC. (BIOR) | Grant/award (A): 12,500 @ $0 · Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2024-03-08 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Grant/award (A): 650,000 (derivative) @ $0 | EDGAR |
| 2023-06-16 | 4 | BIORA THERAPEUTICS, INC. (BIOR) | Grant/award (A): 12,500 @ $0 · Grant/award (A): 12,500 (derivative) @ $0 | EDGAR |
| 2023-03-10 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Grant/award (A): 150,000 (derivative) @ $0 | EDGAR |
| 2023-01-05 | 4 | BIORA THERAPEUTICS, INC. (BIOR) | Disposition to issuer (D): 19 | EDGAR |
| 2022-11-16 | 4 | Lineage Cell Therapeutics, Inc. (LCTX) | Grant/award (A): 1,000,000 (derivative) @ $0 | EDGAR |
| 2022-06-17 | 4 | BIORA THERAPEUTICS, INC. (BIOR) | Grant/award (A): 96,154 @ $0 · Grant/award (A): 148,810 (derivative) @ $0 | EDGAR |
| 2021-11-05 | 4 | PROGENITY, INC. (PROG) | Grant/award (A): 76,754 @ $0 · Grant/award (A): 82,879 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-05 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1892397 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs